Clinical Trials during the SARS-CoV-2 Pandemic
- 14 April 2020
- journal article
- letter
- Published by S. Karger AG in Nephron
- Vol. 144 (5), 248-250
- https://doi.org/10.1159/000507582
Abstract
In this issue of Nephron, Perico, Benigni, and Remuzzi offer a concise overview of the interactions of the SARS-CoV-2 virus, the angiotensin-converting enzyme (ACE) pathway(s), and the cell surface glycoprotein ACE2, and describe the mechanism of cellular SARS-CoV-2 uptake via the endocytosis-lysosomal pathway [1].Keywords
This publication has 3 references indexed in Scilit:
- Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin BlockadeNephron, 2020
- Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Clinical Science, 2020
- Hydroxychloroquine: From Malaria to AutoimmunityClinical Reviews in Allergy & Immunology, 2011